PTC Therapeutics (NASDAQ:PTCT) Research Coverage Started at Scotiabank
Scotiabank initiated coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) in a research report sent to investors on Friday, Marketbeat.com reports. The firm issued a sector perform rating and a $55.00 price objective on the biopharmaceutical company’s stock. A number of other equities analysts have also commented on PTCT. Royal Bank of Canada […]
Scotiabank initiated coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) in a research report sent to investors on Friday, Marketbeat.com reports. The firm issued a sector perform rating and a $55.00 price objective on the biopharmaceutical company’s stock. A number of other equities analysts have also commented on PTCT. Royal Bank of Canada […]
